Please login to the form below

Not currently logged in
Email:
Password:

tecemotide

This page shows the latest tecemotide news and features for those working in and with pharma, biotech and healthcare.

Merck makes $17bn play for Sigma-Aldrich

Merck makes $17bn play for Sigma-Aldrich

had something of a new product drought in recent years, compounded by late-stage failures including recent casualty tecemotide.

Latest news

  • Merck Serono pulls development of lung cancer prospect Merck Serono pulls development of lung cancer prospect

    The phase I/II trial, known as EMR 63325-009, compared tecemotide to placebo in patients on concurrent or sequential chemoradiotherapy. ... Results from the study suggested tecemotide had no effect on the primary endpoint of overall survival or any of

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Tecemotide (Oncothyreon, Merck KGaA, Merck Serono) consists of mucin-1 (MUC-1), a cell surface glycoprotein that is over-expressed and structurally different in approximately 90 per cent of solid tumours ... Tecemotide is in global phase III development

  • Merck Serono puts faith in lung cancer candidate Merck Serono puts faith in lung cancer candidate

    The results of the START study found that tecemotide was unable to improve overall survival in patients with unresectable stage III NSCLC, the primary endpoint in the trial. ... Tecemotide (formerly known as Stimuvax and L-BLP25) is an immunotherapy

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    replacement etc will be sought. Oncothyreon's clinical stage pipeline includes the immunotherapy candidates tecemotide (phase III - Stage III non-small cell lung cancer) and ONT-10 (phase 1 - solid tumour

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics